Granted Patent
B2
US 12,605,366 · App. 17/596,356 · Granted Apr 21, 2026
Telmisartan for the treatment of hypertension in dogs
Inventors:
Anne Michelle Traas (Saint Joseph, MO); Amanda Erickson Coleman (Bogart, GA); Bianca Natália Ferreira De Moura Lourenco (Athens, GA); Kate Elizabeth Creevy (College Station, TX); Scott Alan Brown (Winterville, GA)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to telmisartan or a pharmaceutically acceptable salt thereof as a medicament for the treatment of hypertension in dogs, wherein the therapeutically effective amount of telmisartan is administered in a daily dosage amount that is varied over a treatment period.
Claims (15)
1 . A method for the treatment of hypertension in a dog in need of such treatment, wherein the dog has a systolic blood pressure (SBP) greater than 140 mmHg and the method comprises administration of a therapeutically effective amount of telmisartan or a pharmaceutically acceptable salt thereof to the dog, wherein the therapeutically effective amount of telmisartan is administered in a daily dosage amount that is varied over a treatment period, the daily dosage amount of telmisartan for a first period of time during the treatment period is at least 1.0 mg/kg of body weight, and the daily dosage amount of telmisartan is increased for a second period of time subsequent the first period of time during the treatment period and in which an identified urinary protein-to-creatinine concentration (UPC) ratio is at least 0.5.
2 . The method according to claim 1 , wherein the hypertension is associated with systemic chronic kidney disease (CKD), elevated urinary protein-to-creatinine ratio (UPC) levels and/or hyperthyroidism.
3 . The method according to claim 1 , which comprises administration of an effective amount of the sodium or potassium salt of telmisartan.
4 . Telmisartan according to claim 1 , wherein the hypertension is idiopathic hypertension.
5 . The method according to claim 1 , wherein the daily therapeutically effective amount of telmisartan ranges from 1.0 to 10.0 mg/kg of body weight.
6 . The method according to claim 1 , wherein the daily dosage amount of telmisartan is increased for the second period of time by an incremental amount ranging from 0.25 to 2.50 mg/kg of body weight.
7 . The method according to claim 6 , wherein the daily dosage amount of telmisartan for a first period of time during the treatment period is 1.0 to 1.5 mg/kg of body weight, and the daily dosage amount of telmisartan for the second period of time is 1.75 to 4.0 mg/kg of body weight.
8 . The method according to claim 1 , wherein the daily dosage amount of telmisartan is decreased after the second period of time by an incremental amount ranging from 0.25 to 2.50 mg/kg of body weight.
9 . The method according to claim 1 , wherein the daily dosage amount of telmisartan is decreased after the second period of time based upon measuring the systolic blood pressure (SBP) value measured for the dog.
10 . The method according to claim 9 , wherein daily dosage amount of telmisartan is decreased when the systolic blood pressure (SBP) value measured for the dog decreases after the second period of time by at least 10 mmHg or at least 20 mmHg or by 10 to 150 mmHg, 10 to 100 mmHg, 10 to 80 mmHg, 10 to 50 mmHg, 10 to 30 mmHg, 10 to 20 mmHg, 20 to 150 mmHg, 20 to 100 mmHg, 20 to 80 mmHg, 20 to 50 mmHg, or 20 to 30 mmHg in relation to a baseline SBP value measured for the dog prior to the first period of time.
11 . The method according to claim 1 , wherein the method further comprises administration of at least one other drug to such dog in need of such a treatment.
12 . The method according to claim 11 , wherein the other drug is selected from the group consisting of calcium channel blockers, cardiotonic-calcium sensitizing agents and ACE inhibitors.
13 . The method according to claim 12 , wherein the other drug is selected from the group consisting of amlodipine, pimobendan, levosimendan, ramipril, benazepril and enalapril.
14 . The method according to claim 1 , wherein the hypertension of the dog in need of such treatment is non-refractory to the treatment with ACE inhibitors.
15 . A method for the treatment of hypertension in a dog in need of such treatment, wherein the dog has a systolic blood pressure (SBP) greater than 140 mmHg and the method comprises administration of a therapeutically effective amount of telmisartan or a pharmaceutically acceptable salt thereof to the dog, wherein the therapeutically effective amount of telmisartan is administered in a daily dosage amount that is varied over a treatment period, a first daily dosage amount of telmisartan is administered for a first period of time during the treatment period, and a second daily dosage amount of telmisartan is administered for a second period of time subsequent the first period of time during the treatment period and based upon a change in an identified urinary protein-to-creatinine concentration (UPC) ratio determined for the dog.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 21, 2025
From: BOEHRINGER INGELHEIM ANIMAL HEALTH INC.
To: BOEHRINGER INGELHEIM VETMEDICA GMBH
Reel/Frame 070584/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 22, 2022
From: TRAAS, ANNE MICHELLE
To: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
Reel/Frame 059675/0647 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 22, 2022
From: COLEMAN, AMANDA ERICKSON; FERREIRA DE MOURA LOURENCO, BIANCA NATÁLIA; CREEVY, KATE ELIZABETH; BROWN, SCOTT ALAN
To: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
Reel/Frame 059676/0651 →
Continuity (2)
Provisional Application
62871749
· Jul 9, 2019
References Cited (285)
US 4355040A
· Furukawa et al.
· 1982
[cited by applicant]
US 4448778A
· Lynch
· 1984
[cited by applicant]
US 4880804A
· Carini et al.
· 1989
[cited by applicant]
US 5237997A
· Greubel et al.
· 1993
[cited by applicant]
US 5331162A
· Silver et al.
· 1994
[cited by applicant]
US 5591762A
· Hauel et al.
· 1997
[cited by applicant]
US 5846962A
· Suzuki et al.
· 1998
[cited by applicant]
US 5965592A
· Buhlmayer et al.
· 1999
[cited by applicant]
US 6028091A
· Hill
· 2000
[cited by applicant]
US 6204281B1
· Webb et al.
· 2001
[cited by applicant]
US 6331162B1
· Mitchell
· 2001
[cited by applicant]
US 6358986B1
· Schneider
· 2002
[cited by applicant]
US 6410742B1
· Schneider
· 2002
[cited by applicant]
US 6589547B1
· Igari et al.
· 2003
[cited by applicant]
US 6737432B2
· Donsbach et al.
· 2004
[cited by applicant]
US 7208508B2
· Daemmgen et al.
· 2007
[cited by applicant]
US 8005624B1
· Starr
· 2011
[cited by applicant]
US 8772278B2
· Stark et al.
· 2014
[cited by applicant]
US 8838209B2
· Mestha et al.
· 2014
[cited by applicant]
US 8870782B2
· Futatsuyama et al.
· 2014
[cited by applicant]
US 8871795B2
· Mohr et al.
· 2014
[cited by applicant]
US 9011346B2
· Wiard et al.
· 2015
[cited by applicant]
US 9241637B2
· Wiard et al.
· 2016
[cited by applicant]
US 9308197B2
· Stark et al.
· 2016
[cited by applicant]
US 9585873B2
· Stark et al.
· 2017
[cited by applicant]
US 9833151B2
· Wiard et al.
· 2017
[cited by applicant]
US 9949954B2
· Stark et al.
· 2018
[cited by applicant]
US 9949964B2
· Racheboeuf
· 2018
[cited by applicant]
US 20020037095A1
· Cheng
· 2002
[cited by applicant]
US 20020094997A1
· Schneider et al.
· 2002
[cited by applicant]
US 20030144583A1
· Cheng et al.
· 2003
[cited by applicant]
US 20040219208A1
· Kawamura et al.
· 2004
[cited by applicant]
US 20050070594A1
· Kauschke et al.
· 2005
[cited by applicant]
US 20050186274A1
· Kohlrausch
· 2005
[cited by applicant]
US 20050272649A1
· Hruska et al.
· 2005
[cited by applicant]
US 20070026026A1
· Delmarre et al.
· 2007
[cited by applicant]
US 20070155679A1
· Daemmgen et al.
· 2007
[cited by applicant]
US 20080183232A1
· Voss et al.
· 2008
[cited by applicant]
US 20100100160A1
· Edman et al.
· 2010
[cited by applicant]
US 20110260176A1
· Onoe et al.
· 2011
[cited by applicant]
US 20120245439A1
· Andre et al.
· 2012
[cited by applicant]
US 20130030259A1
· Thomsen et al.
· 2013
[cited by applicant]
US 20160045117A1
· Liu et al.
· 2016
[cited by applicant]
US 20170127959A1
· Paulussen et al.
· 2017
[cited by applicant]
US 20170188963A1
· Banet et al.
· 2017
[cited by applicant]
US 20170245767A1
· Ferber et al.
· 2017
[cited by applicant]
US 20180199824A1
· Centen et al.
· 2018
[cited by applicant]
US 20180360323A1
· Lui
· 2018
[cited by applicant]
US 20210106564A1
· Albrecht et al.
· 2021
[cited by applicant]
US 20210113155A1
· Anliker et al.
· 2021
[cited by applicant]
US 20210244302A1
· Lizio et al.
· 2021
[cited by applicant]
US 20220218671A1
· Traas et al.
· 2022
[cited by applicant]
US 20250195525A1
· Haag-Diergarten et al.
· 2025
[cited by applicant]
CA 2352436A1
· 2000
[cited by applicant]
CA 2463146A1
· 2003
[cited by applicant]
CN 1422153A
· 2003
[cited by applicant]
CN 1765362A
· 2006
[cited by applicant]
CN 1849998A
· 2006
[cited by applicant]
CN 101522191A
· 2009
[cited by applicant]
CN 102300538A
· 2011
[cited by applicant]
CN 102458363A
· 2012
[cited by applicant]
CN 108801421A
· 2018
[cited by applicant]
CN 110251105A
· 2019
[cited by applicant]
DE 1023027B
· 1958
[cited by applicant]
DE 10335027A1
· 2005
[cited by applicant]
EP 0253310B1
· 1988
[cited by applicant]
EP 0323841B1
· 1989
[cited by applicant]
EP 0324377B1
· 1989
[cited by applicant]
EP 0420237B1
· 1991
[cited by applicant]
EP 0443983B1
· 1991
[cited by applicant]
EP 0459136B1
· 1991
[cited by applicant]
EP 0475206A2
· 1992
[cited by applicant]
EP 0502314B1
· 1992
[cited by applicant]
EP 0504888A1
· 1992
[cited by applicant]
EP 0514198A1
· 1992
[cited by applicant]
EP 1579862A1
· 2005
[cited by applicant]
EP 1908469A1
· 2008
[cited by examiner]
EP 2420232A2
· 2012
[cited by applicant]
JP H11315034A
· 1999
[cited by applicant]
JP 2002172094A
· 2002
[cited by applicant]
JP 2006502194A
· 2006
[cited by applicant]
JP 2008104667A
· 2008
[cited by applicant]
JP 2008518888A
· 2008
[cited by applicant]
JP 2008237686A
· 2008
[cited by applicant]
JP 2013169464A
· 2013
[cited by applicant]
JP 2017000415A
· 2017
[cited by applicant]
RU 2008135692A
· 2010
[cited by applicant]
WO 1985003211A1
· 1985
[cited by applicant]
WO 1991014679A1
· 1991
[cited by applicant]
WO 1992010182A1
· 1992
[cited by applicant]
WO 1993020816A1
· 1993
[cited by applicant]
WO 1995026188A1
· 1995
[cited by applicant]
WO 1996031234A1
· 1996
[cited by applicant]
WO 1997049392A1
· 1997
[cited by applicant]
WO 1999044590A1
· 1999
[cited by applicant]
WO 2000043370A1
· 2000
[cited by applicant]
WO 2001078699A2
· 2001
[cited by applicant]
WO 2002092081A1
· 2002
[cited by applicant]
WO 2003004068A1
· 2003
[cited by applicant]
WO 2003037876A1
· 2003
[cited by applicant]
WO 2004014308A2
· 2004
[cited by applicant]
WO 2004028505A1
· 2004
[cited by applicant]
WO 2005070463A2
· 2005
[cited by applicant]
WO 2005123070A1
· 2005
[cited by applicant]
WO 2006048208A1
· 2006
[cited by applicant]
WO 2007092469A2
· 2007
[cited by applicant]
WO 2008040774A2
· 2008
[cited by applicant]
WO 2008110599A1
· 2008
[cited by applicant]
WO 2010063114A1
· 2010
[cited by applicant]
WO 2010133638A1
· 2010
[cited by applicant]
WO 2015127193A1
· 2015
[cited by applicant]
WO 2017171228A1
· 2017
[cited by applicant]
WO 2019008077A1
· 2019
[cited by applicant]
WO 2019170903A1
· 2019
[cited by applicant]
WO 2021006941A1
· 2021
[cited by applicant]
WO 2021006942A1
· 2021
[cited by applicant]
WO 2021074292A1
· 2021
[cited by applicant]
WO 2021074297A1
· 2021
[cited by applicant]
WO 2024240632A1
· 2024
[cited by applicant]
WO 2024240633A1
· 2024
[cited by applicant]
WO 2025125409A1
· 2025
[cited by applicant]
Gonzalez, S.G. et al., “Telmisartan versus benazepril on the management of systemic hypertension in dogs with hyperadrenocorticism” Journal of Veterinary Internal Medicine, Apr. 2019, vol. 33, No. 2, p. 1083, Abstract N…
[cited by applicant]
Yusuke Sakai, et al., Antiproteinuric effect of telmisartan in dogs with protein-leaking nephropathy, Japanese Association of Veterinary Nephrology and Urology) 2018, vol. 10, No. 1, pp. 44-49.
[cited by applicant]
Harkevič D.A., Farmakologiâ [Pharmacology], Moscow, 2006, p. 62.
[cited by applicant]
Written Opinion of the International Search Authority WO2021006941, Jan. 14, 2021.
[cited by applicant]
Written Opinion of the International Search Authority WO2021006942, Jan. 14, 2021.
[cited by applicant]
Acierno et al., ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med. 2018, 32, 1803-1822.
[cited by applicant]
Ames et al. Effects of high doses of enalapril and benazepril on the pharmacologically activated renin-angiotensin-aldosterone system in clinically normal dogs. Am J Vet Res 2015; 76:1041-50.
[cited by applicant]
Brown et al., Evaluation of the effects of inhibition of angiotensin converting enzyme with enalapril in dogs with induced chronic renal insufficiency. Am J Vet Res 2003; 64, 321-327.
[cited by applicant]
Brown et al. Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J Vet Intern Med 2007; 21:542-58.
[cited by applicant]
Brown et al. IRIS Canine GN Study Group Standard Therapy Subgroup, Consensus Recommendations for Standard Therapy of Glomerular Disease in Dogs. J Vet Intern Med 2013; 27:S27-43.
[cited by applicant]
Bugbee et al., Telmisartan Treatment of Refractory Proteinuria in a Dog. Journal of Veterinary Internal Medicine, 2014, vol. 28, No. 6, 1871-1874.
[cited by applicant]
Caro-Vadillo et al., Effect of a combination of telmisartan and amlodipine in hypertensive dogs. Veterinary Record Case Reports 2018, vol. 6 No. 2, p. e000471.
[cited by applicant]
European Medicines Agency. PRAC recommends against combined use of medicines affecting the renin-angiotensin (RAS) system, 2014. EMA EMA/196502/2014.
[cited by applicant]
Geigy et al. Occurrence of systemic hypertension in dogs with acute kidney injury and treatment with amlodipine besylate. J Small Anim Pract 2011; 52:340-6.
[cited by applicant]
Grauer et al., Effects of enalapril versus placebo as a treatment for canine idiopathic glomerulonephritis. J Vet Intern Med 2000, 14, 526-533.
[cited by applicant]
Grodecki et al., Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor. J Comp Pathol 1997, 117, 209-225.
[cited by applicant]
Konta et al.,Evaluation of the inhibitory effects of telmisartan on drug-induced renin-angiotension-aldosterone system activation in normal dogs. Journal of Veterinary Cardiology 2018, vol. 20 No. 5, p. 376-383.
[cited by applicant]
Kwon et al.,Successful management of proteinuria and systemic hypertension in a dog with renal cell carcinoma with surgery, telmisartan, and amlodipine. Can Vet J 2018, 59(7), 759-762.
[cited by applicant]
Lorenço, Efficacy of Telmisartan for the Treatment of Persistent Canine Renal Proteinuria. AVCIM Forum 2019. Published May 21, 2019 at https://www.eventscribe.com/2019/ACVIM/agenda.asp?pfp=agenda.
[cited by applicant]
Schierok et al., Effects of telmisartan on Renal Excretory Function in Conscious Dogs. Journal of International Medical Research 2001, 131-139.
[cited by applicant]
Schmieder et al. A guide for easy- and difficult-to-treat hypertension. Int J Cardiol 2014; 172:17-22.
[cited by applicant]
Tjostheim et al. Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs. J Vet Intern Med 2016; 30:951-7.
[cited by applicant]
Wienen et al. A Review on Telmisartan: A Novel, Long-Acting Angiotensin II-Receptor Antagonist. Cardiovasc Drug Rev 2000;18:127-54.
[cited by applicant]
Martin, José FV, Luciana NC Martin, and José P. Cipullo. “Pharmacologic treatment for prehypertension: to treat or not to treat?” Recent Patents on Cardiovascular Drug Discovery (Discontinued) 4.2 (2009): 133-141.
[cited by applicant]
Maruo et al., “Polymorphism of UDP-Glucuronosyltransferase and Drug Metabolism.” Current Drug Metabolism, vol. 6, 2005, pp. 91-99.
[cited by applicant]
Mathur et al., “Evaluation of a technique of inducing hypertensive renal insufficiency in cats”. American Journal of Veterinary Research, vol. 65, No. 7, Jul. 2004, pp. 1006-1013.
[cited by applicant]
Mishina et al., “Non-invasive Blood Pressure Measurements in Cats: Clinical Significance of Hypertension Associated with Chronic Renal Failure.” The Journal of Veterinary Medical Science, vol. 60, No. 7, 1998, pp. 805-8…
[cited by applicant]
Norikazu et al., “Comparison of angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors on a dog suffering mild mitral insufficiency”. Annual Meeting of the Japanese Society of Veterinary Scienc…
[cited by applicant]
Ono et al., “Characteristics of the Long-Acting Sartan Telmisartan”. Circulation Control, vol. 23, No. 4, 2002, pp. 462-466.
[cited by applicant]
Osweiler, Gary D., “Toxicological Concepts: Factors that Influence Toxicology”, General Toxicological Principles, in Small Animal Toxicology, Elsevier, Inc., St. Louis, MO, 2006, p. A17.
[cited by applicant]
Pace, Charlotte. “Canine and feline hypertension.” The Veterinary Nurse 14.2 (2023): 75-82.
[cited by applicant]
Perrier et al., “In vitro N-glucuronidation of SB 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions.” Abstract, The Journal of Pharmacolog…
[cited by applicant]
Pershadsingh et al., “Insulin-Sensitizing Effects of Telmisartan”. Diabetes Care, vol. 27, No. 4, Apr. 2004, p. 1015.
[cited by applicant]
Polzin et al., “Treating Feline Kidney Disease: An Evidence-Baed Approach”. North American Veterinary Conference Proceedings, Jan. 7, 2006, pp. 1-6. [Accessed at http://www.iknowledgenow.com/article.cfm?documentID=2817t…
[cited by applicant]
Resampling (statistics)(retrieved from internet on Apr. 7, 2025) Retrieved from ,https://en.wikpedia.org/w/index.php?title=Resampling_(statistics) & oldid=917587664. Sep. 24, 2019.
[cited by applicant]
Rodriguez-Iturbe et al., “Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage”. Kidney International, vol. 68, 2005, pp. 2131-2142.
[cited by applicant]
Schiweck et al., “Sugar Alcohols”. Ullmann's Encyclopedia of Industrial Chemistry, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 2012, pp. 1-37.
[cited by applicant]
Semintra—Prescription Animal Remedy, Jun. 6, 2016, Retrieved From the Internet: http://files.boehringer.com.au/files/CMI/Semintra%20ANZ.pdf [retrieved on Oct. 12, 2018].
[cited by applicant]
Sharpe, Miriam, Blair Jarvis, and Karen L. Goa. “Telmisartan: a review of its use in hypertension.” Drugs 61.10 (2001): 1501-1529.
[cited by applicant]
Snively et al., “Chronic Kidney Disease: Prevention and Treatment of Common Complications”. American Family Physicians, vol. 70, No. 10, Nov 2004m pp. 1921-1928.
[cited by applicant]
Stebbins et al., “Spinal angiotensin II influences reflex cardiovascular responses to muscle contraction”. American Journal of Physiology, vol. 269, No. 4, Part 2, 1995pp. R864-R868.
[cited by applicant]
Suga et al., “Angiotensin II type 1 receptor blockade ameliorates tubulointerstitial injury induced by chronic potassium deficiency”. 2002, Kidney International, vol. 61, pp. 951-958.
[cited by applicant]
Summary of Product Information—Semintra, European Medicine Agency, Feb. 28, 2013, pp. 1-32, retrieved from the Internet: URL:https://www.ema.europa.eu/documents/product-information/semintra-epar-product-information_en.p…
[cited by applicant]
Suzuki, Hiromichi, “Investigation of Clinical Benefits of Different Types of ARBs in Treatment of Hypertension Associated with Renal Disease.” Progress in Medicine, vol. 26, No. 7, Jul. 2006, pp. 145-151 (1669-1674).
[cited by applicant]
Syme et al., “Survival of Cats with Naturally Occurring Chronic Renal Failure Is Related to Severity of Proteinuria”. Journal of Veterinary Internal Medicine, vol. 20, No. 3, 2006, pp. 528-535.
[cited by applicant]
Tran et al., “Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release”. Journal of Controlled Release, vol. 129, No. 1, 2008, pp. 59-65.
[cited by applicant]
Villar et al., “Ibuprofen, Aspirin and Acetaminophen Toxicosis and Treatment in Dogs and Cats”. Veterinary Human Toxicology, vol. 40, No. 3, 1998, pp. 156-162.
[cited by applicant]
Web site: www.merck.com “Chronic Kidney Disease,” accessed on Dec. 13, 2010.
[cited by applicant]
Web site: www.merck.com “Tubulointerstitial Nephritis,” accessed on Jun. 1, 2009.
[cited by applicant]
White, et al., “Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period,” Amer Journal of Hypertension, vol. 17, Issu…
[cited by applicant]
Written Opinion of the International Search Authority for PCT/EP2007/060531 mailed May 19, 2008.
[cited by applicant]
Written Opinion of the International Search Authority PCT/EP/020079045 (WO2021074297), mailed on Feb. 9, 2021.
[cited by applicant]
Written Opinion of the International Search Authority PCT/EP/2018/068189 (WO2019008077), mailed on Oct. 26, 2018.
[cited by applicant]
Written Opinion of the International Search Authority PCT/EP2020/079040 (WO2021074292A1), mailed on Feb. 9, 2021.
[cited by applicant]
Written Opinion of the International Searching Authority for PCT/EP2010/056895 mailed on Aug. 3, 2010.
[cited by applicant]
Xiao et al., “Regional Hemodynamic Effects of the AT1 Receptor Antagonist CV-11974 in Conscious Renal Hypertensive Rats”. Hypertension, vol. 26, 1995, pp. 989-997.
[cited by applicant]
Xue, Jintong. “Chapter 13. Hypertensive Disease”. Practical Handbook for the Diagnosis and Treatment of Cardiovascular Disease, First Edition, Zhengzhou University Press, 2005, pp. 480-508.
[cited by applicant]
Yoshida et al., “Metabolic effect of All receptor antagonists.” Ketsuatsu (Blood Pressure), vol. 9, No. 8, 2002, pp. 802-806. (Abstract in English).
[cited by applicant]
Yu, Guoqiang, et al. “Time-dependent blood flow and oxygenation in human skeletal muscles measured with noninvasive near-infrared diffuse optical spectroscopies.” Journal of biomedical optics 10.2 (2005): 024027-024027.
[cited by applicant]
Zenchun Li et al. “Progress in Drug Therapy for Dialated Cardiomyopathy” Chinese Medical Abstracts—Geriatrics, 2002, vol. 11, No. 1, pp. 69-72 (Chinese Language).
[cited by applicant]
“Kidney Disease”, The Medical Dictionary, pp. 1-5. [Accessed at: http://medical-dictionary.thefreedictionary.com/kidney+disease; accessed Nov. 1, 2015].
[cited by applicant]
Zenchun Li et al. “Progress in Drug Therapy for Dialated Cardiomyopathy” Chinese Medical Abstracts—Geriatrics, 2002, vol. 11, No. 1, pp. 69-72 English translation of introduction paragraph + cited paragraph.
[cited by applicant]
Abstract in English for CN1765362A, 2006.
[cited by applicant]
Abstract in English for JPH11315034A1, 1999.
[cited by applicant]
Adamson et al., “The Fate of Sulphadimethoxine in Primates Compared with other Species”. Biochemical Journal, vol. 118, 1970, pp. 41-45.
[cited by applicant]
Allen, Andrew L., “The Diagnosis of Acetaminophen toxicosis in cats”., The Canadian Veterinary Journal, vol. 44, No. 6, Jun. 2003, pp. 509-510.
[cited by applicant]
Anonymously, “Bootstrapping (statistics)”, https://web.archive.org/web/2019040854026/https://en.wikepedia.or(wiki/Bootstrapping_(statistics), Wikipedia, XP093129092, Publication date Apr. 8, 2019, 13 pages.
[cited by applicant]
Arenas-Lopez et al., Accuracy of enteral syringes with commonly prescribed paediatric liquid medicines. Archives of Disease in Childhood 2017, 102, 655-659. Published Feb. 24, 2017.
[cited by applicant]
Asiedu-Gyekye et al. “Does losartan prevent cerebral edema? A preliminary study using a vascular compartment model”. Medical Science Monitor, vol. 9, No. 3, Mar. 2003, pp. BR127-BR130.
[cited by applicant]
Barnett, Anthony H., et al. “Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.” New England Journal of Medicine 351.19 (2004): 1952-1961.
[cited by applicant]
Berny et al., “Animal Poisoning in Europe. Part 2: Companion Animals”. The Veterinary Journal, vol. 183, 2010, pp. 255-259.
[cited by applicant]
Bile Excreted Sustained AT1 Receptor Blocker (alternatively ‘Biliary excretion type AT1 receptor blocker with prolonged action’), Japanese Pharmacopoeia, Telmisartan tablets, package insert, Nihon Generic Co., Ltd. (Jun…
[cited by applicant]
Bile Excreted Sustained AT1 Receptor Blocker (alternatively ‘Biliary excretion type AT1 receptor blocker with prolonged action’), Japanese Pharmacopoeia, Telmisartan tablets, package insert, Nihon Generic Co., Ltd. (Jun…
[cited by applicant]
Buoncompagni et al., “Treatment of Systemic Hypertension Associated With Kidney Disease.” Compendium: Continuing Education for Veterinarians, Vetlearn.com, 2013, pp. E1-E6.
[cited by applicant]
Burnier et al., “Angiotensin Il receptor antagonists”. The Lancet, vol. 355, 2000, pp. 637-645.
[cited by applicant]
Caldwell et al., “Drug Metabolism in ‘Exotic’ Animals”. European Journal of Drug Metabolism and Pharmacokinetics, No. 2, 1978, pp. 61-66.
[cited by applicant]
Caldwell et al., “Species Differences in Xenobiotic Conjugation”. Xenobiotic Metabolism and Disposition, Proceedings of the 2nd International ISSX Meeting, Kobe, Japan, May 16-20, 1988, pp. 217-224.
[cited by applicant]
Champion et al., “Analysis of the Effects of Candesartan on Responses to Angiotensin II in the Hindquarters Vascular Bed of the Cat”. Journal of the American Society of Nephrology, vol. 10, 1999, pp. S101-S103.
[cited by applicant]
Cingolani et al., “The Positive Inotropic Effect of Angiotensin II: Role of Endothelin-1 and Reactive Oxygen Species”. Hypertension, vol. 47, No. 4, Apr. 2006, pp. 727-734.
[cited by applicant]
Conlon, Peter D., “Nonsteroidal Drugs Used in the Treatment of Inflammation”. Clinical Pharmacology, vol. 18, No. 6, 1988, pp. 1115-1131.
[cited by applicant]
Coronel et al., “Hypertension Treatment in Nondiabetic Advanced Chronic Kidney Disease Patients with Irbesartan. Effect on Serum Uric Acid”. Abstract, Journal of Hypertension, vol. 23, Supp. 2, 2005, p. S65.
[cited by applicant]
Court et al., “Molecular Basis for Deficient Acetaminophen Glucuronidation in Cats an Interspecies Comparison of Enzyme Kinetics in Liver Microsomes,” 1997, Biochemical Pharmacology, vol. 53, pp. 1041-1047.
[cited by applicant]
Court et al., “Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms”. Pharmacogenetics, vol. 10, 200…
[cited by applicant]
Desmet, Lien, and Jeroen van der Meer. “Antihypertensive treatment with telmisartan in a cat with amlodipine-induced gingival hyperplasia.” Journal of Feline Medicine and Surgery Open Reports 3.2 (2017): 205511691774523…
[cited by applicant]
Ebner et al., “Disposition and Chemical Stability of Telmisartan 1-O-acylglucuronide”. 1999, The American Society for Pharmacology & Experimental Therapeutics, vol. 27, No. 10, pp. 1143-1149.
[cited by applicant]
Ebner et al., “In vitro flucuronidation of the angiontensin II receptor antagonist telmisartan in the cat: a comparison with other species.” Journal of Vetrinary Pharmacology and Therapeutics, vol. 36, 2012, pp. 154-160.
[cited by applicant]
Ettinger et al., “Therapeutic Considerations in Medicine and Disease”, Textbook of Veterinary Internal Medicine Diseases of the Dog and Cat, Sixth Edition, vol. 1, Section VI, Table 143, 2005, pp. 530-531.
[cited by applicant]
Garrison et al., “[Pro11, D-Ala12] angiotensin I has rapid onset vasoconstrictor activity in the cat”. American Journal of Physiology-Endocrinology and Metabolism, vol. 273, No. 6, 1997, pp. E1059-E1064.
[cited by applicant]
Glaus, A., J. Elliott, and B. Albrecht. “Efficacy of telmisartan in hypertensive cats: results of a large European Clinical Trial 27th ECVIM-CA Congress.” Malta: John Wiley & Sons, Ltd (2017). Wiley & Sons, Ltd (2017).
[cited by applicant]
Grauer, Gregory, “ACE Inhibitors and CKD”, 2 pages. [Accessed at : http://www.dvm360storage.com/cvc/proceedings/dc/Urology/Grauer/Grauer,Gregory_ACE_Inhibitors_and_CKD.pdf on Feb. 5, 2015].
[cited by applicant]
Guangxi Agricultural College et al., “Oxidation in acidic solutions”. Organic Chemistry, Guangxi People's Publishing House, Dec. 1982, p. 235.
[cited by applicant]
Harley et al., “Proteinuria in dogs and cats.” Canadian Veterinary Journal, vol. 53, Jun. 2012, pp. 631-638.
[cited by applicant]
Hiwada, Kunio, “Presentation of New Drug: Telmisartan”. Vascular Biology & Medicine, vol. 3, No. 5, 2002, pp. 571-576.
[cited by applicant]
Honjo et al., “Possible Beneficial Effect of Telmisartan on Glycemic Control in Diabetic Subjects”. Diabetes Care, vol. 28, No. 2, Fe. 2005, p. 498.
[cited by applicant]
Huskey et al., “N-glucuronidation reactions. I. Tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys, and humans.” Abstract, Drug Metabolism and Disp…
[cited by applicant]
Iino et al., “Renoprotective Effect of Losartan in Comparison to Amlodipine in Patients with Chronic Kidney Disease and Hypertension—a Report of the Japanese Losartan Therapy Intended for the Global Reneal Protection in…
[cited by applicant]
International Search Report for PCT/EP2007/060531 mailed May 19, 2008.
[cited by applicant]
Israili, Z.H., “Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension”. Journal of Human Hypertension, vol. 14, Suppl. 1, 2000, pp. S73-S86.
[cited by applicant]
Jensen et al., “Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease.” American Journal of Veterinary Research, vol. 58, No. 5, May 1997,…
[cited by applicant]
Kemper et al., “Metabolism: A Determinant of Toxicology”. Principles and Methods of Toxicology, 5th Edition, Chapter 3, Informa Healthcare USA, New York, NY, 2008, pp. 139-142.
[cited by applicant]
Koide et al., “Hypertrophic response to hemodynamic overload: role of load vs. renin-angiotensin system activation”. American Journal of Physiology—Heart, vol. 276, 1999, pp. H350-H358.
[cited by applicant]
Kondo et al., “Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid chromatography/electrospray tandem mass spectrometry following chemical der…
[cited by applicant]
Kumari et al., “Effect of Pre- and Posttreatment of Losartan in Feline Model of Myocardial Ischemic-Reperfusion Injury”. Methods and Findings in Experimental and Clinical Pharmacology, vol. 26, No. 1, 2004, pp. 39-45.
[cited by applicant]
Lactitol JEFC 1996, published in FNP 52 Add 4 (1996).
[cited by applicant]
Lazaro et al., “Forum Original Research Communication: Long-Term Blood Pressure Control Prevents Oxidative Renal Injury.” Antioxidants & Redox Signaling, vol. 7, Nos. 9 & 10, 2005, pp. 1285-1293.
[cited by applicant]
Lefebvre et al., “Angiotensin-converting enzyme inhibitors in the therapy of renal diseases”. Journal of Veterinary Pharmacology and Therapeutics, vol. 27, 2004, pp. 265-281.
[cited by applicant]
Li et al., “Efficacy evaluation of Telmisartan in treatment of dilated cardiomyopathy with heart failure”. Chinese Heart Journal, vol. 18, No. 4, 2006, pp. 427-429.
[cited by applicant]
Lim et al., “Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy”. Circulation, vol. 103, Feb. 2001, pp. 789-791. [Accessed at http://circ.ahaqjournals.o…
[cited by applicant]
Malike et al., “Permethrin Spot on Intoxication of Cats: Literature review and survey of veterinary practioners in Australia”. Journal of Feline Medicine and Surgery, vol. 12, 2010, pp. 5-14.
[cited by applicant]
Maltilol, JEFCA 1996, published in FNP 52 Add 4 (1996).
[cited by applicant]
Sent, U., et al. “Comparison of efficacy of long-term oral treatment with telmisartan and benazepril in cats with chronic 1 kidney disease.” Journal of veterinary internal medicine 29.6 (2015): 1479-1487.
[cited by applicant]
Written Opinion of the International Search Authority PCT/EP2024/05884 (WO2025125409A1) mailed on Jul. 2, 2025.
[cited by applicant]
Barber P.J., “The Kidney,” Editors: Chandler E.A., Gaskell C.J., Gaskell R.M., Feline Medicine and Therapeutics, 3rd Edition, Blackwell Publishing, 2004.
[cited by applicant]
Chakrabarti S., et al., “Clinicopathological Variables Predicting Progression of Azotemia in Cats with Chronic Kidney Disease,” Journal of Veterinary Internal Medicine, Mar. 23, 2012, vol. 26, No. 2, pp. 275-281, J.B. L…
[cited by applicant]
Chen J., “Small Animal Diseases,” Beijing Agricultural University Press, The First Edition, First Print, Apr. 1993, pp. 6-10 (8 Pages).
[cited by applicant]
Cupisti A., et al., Biomedicine and Pharmacotherapy, 2003, vol. 57, No. 3-4, pp. 169-172.
[cited by applicant]
Extended European Search Report for European Application No. 23204038.6, dated Feb. 7, 2024, 09 Pages.
[cited by applicant]
Extended European Search Report for European Application No. EP11186070.6, dated Mar. 8, 2012, 14 Pages.
[cited by applicant]
Extended European Search Report for European Application No. EP11186078.9, dated Apr. 4, 2012, 19 Pages.
[cited by applicant]
Extended European Search Report for European Application No. EP11186080.5, dated Mar. 21, 2012, 15 Pages.
[cited by applicant]
Karallied Viberti, Journal of Human Hypertension, 2006.
[cited by applicant]
Merck: “Chronic Kidney Disease (Chronic Renal Failure),” accessed on Dec. 13, 2010, 07 Pages.
[cited by applicant]
Partial European Search Report for European Application No. 06121905.1, dated Mar. 6, 2007, 15 Pages.
[cited by applicant]
Polzin D.J., et al., “Chronic Kidney Disease,” Textbook of Veterinary Internal Medicine, 6th Edition, W.B. Saunders Company, 2005.
[cited by applicant]
Polzin, et al., “Textbook of Veterinary Internal Medicine,” 2005, vol. 2, pp. 1756-1785.
[cited by applicant]
Remuzzi, et al., Journal of Clinical Investigation, 2006, vol. 116, No. 2, pp. 288-296.
[cited by applicant]
Rysava R., et al., “Effect Of Telmisartan On Blood Pressure Control And Kidney Function In Hypertensive, Proteinuric Patients With Chronic Kidney Disease,” Blood Pressure Monitoring, 2005, vol. 10, No. 4, pp. 207-213.
[cited by applicant]
Sharma A.M., et al., “Telmisartan in Patients With Mild/Moderate Hypertension and Chronic Kidney Disease,” Clinical Nephrology, 2005, vol. 63, No. 4, pp. 1-8.
[cited by applicant]
The Merck Manual: “Chronic Kidney Diseases,” 1 Page, [Retrieved On Aug. 4, 2010] Retrieved From URL: www. merck.com.
[cited by applicant]
Wolf A.M., North American Veterinary Congress, 2006.
[cited by applicant]